Atherogenic dyslipidemia is a critical factor in developing CVD related to Metabolic Syndrome. While atherogenic dyslipidemia plays a prominent role in the development of atherosclerosis, endothelial dysfunction works alongside atherogenic dyslipidemia to contribute to the development of CVD as endothelial dysfunction also promotes atherosclerotic plaque development. This effect may provide to be synergistic in patients with MS, as endothelial dysfunction is predominantly found in this population. Other modes of action exist in MS which directly influence atherogenic dyslipidemia. Elevated FFA, commonly observed as a result from IR, accumulate in the liver causing a high FFA flux. This can result in increased production of very low density lipoproteins, triglycerides, apolipoprotein B, and a reduction in high density lipoproteins. High triglycerides and apolipoprotein B along with low levels of high density lipoproteins are known to be atherogenic and their respective concentrations are used to determine atherogenic dyslipidemia.
Scholarly open access Journal of Diabetes & Metabolism is focused on the causes, diagnosis and treatment of the diabetes & related complications. It publishes the article on the study of the basic level to genetic level of the diabetes and the related diseases.
Last date updated on July, 2014